• Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=27723727).
  

PubMed=24440720; DOI=10.1016/j.celrep.2013.12.032; PMCID=PMC4041390
Chudnovsky Y., Kim D., Zheng S.-Y., Whyte W.A., Bansal M., Bray M.-A., Gopal S., Theisen M.A., Bilodeau S., Thiru P., Muffat J., Yilmaz O.H., Mitalipova M., Woolard K.D., Lee J., Nishimura R., Sakata N., Fine H.A., Carpenter A.E., Silver S.J., Verhaak R.G.W., Califano A., Young R.A., Ligon K.L., Mellinghoff I.K., Root D.E., Sabatini D.M., Hahn W.C., Chheda M.G.
ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state.
Cell Rep. 6:313-324(2014)

PubMed=25184684; DOI=10.1371/journal.pone.0106694; PMCID=PMC4153667
Holmberg Olausson K., Maire C.L., Haidar S., Ling J., Learner E., Nister M., Ligon K.L.
Prominin-1 (CD133) defines both stem and non-stem cell populations in CNS development and gliomas.
PLoS ONE 9:e106694.1-e106694.11(2014)

PubMed=25366336; DOI=10.1093/neuonc/nou303; PMCID=PMC4482855
Green A.L., Ramkissoon S.H., McCauley D., Jones K., Perry J.A., Hsu J.H.-R., Ramkissoon L.A., Maire C.L., Hubbell-Engler B., Knoff D.S., Shacham S., Ligon K.L., Kung A.L.-J.
Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
Neuro-oncol. 17:697-707(2015)

PubMed=27723727; DOI=10.1038/nbt.3697; PMCID=PMC5142231
Stevens M.M., Maire C.L., Chou N., Murakami M.A., Knoff D.S., Kikuchi Y., Kimmerling R.J., Liu H.-Y., Haidar S., Calistri N.L., Cermak N., Olcum S., Cordero N.A., Idbaih A., Wen P.Y.-C., Weinstock D.M., Ligon K.L., Manalis S.R.
Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate.
Nat. Biotechnol. 34:1161-1167(2016)

PubMed=34610309; DOI=10.1016/j.celrep.2021.109788
Stockslager M.A., Malinowski S., Touat M., Yoon J.C., Geduldig J., Mirza M., Kim A.S., Wen P.Y.-C., Chow K.-H., Ligon K.L., Manalis S.R.
Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models.
Cell Rep. 37:109788.1-109788.12(2021)